Get started
Author

Pervin Can Sanci

Observed names: CAN ŞANCI, PERVİN, Can Şanci, Pervin, Can Şancı, Pervin, P. Can Sanci, Pervin Can, Pervin Can Sancı, Pervin Can Şanci, Pervin Can Şancı, Pervin Sancı
ORCID: 0000-0002-5310-5557
Observed ORCID: 0000-0002-5310-5557
OpenAlex ID: A5133621391
Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617
2023 · Elif Şahin, Umut Kefeli, et al. · Medicine · 25
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
2024 · Hasan Cagri Yildirim, Caner Kapar, et al. · Journal of Chemotherapy · 9
HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer—A Multicenter Retrospective Cohort Study
2025 · Mustafa Seyyar, Pervin Can Şancı, et al. · Journal of Clinical Medicine · 6
PDF
Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
2025 · Ogur Karhan, Serdar İleri, et al. · Therapeutic Advances in Medical Oncology · 5
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
2024 · İsmail Beypınar, Hacer Demir, et al. · Breast Cancer Research and Treatment · 4
Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer
2026 · Emel Mutlu Ozkan, Ibrahim Karadağ, et al. · Expert Review of Anticancer Therapy · 3
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Medicina · 1
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients
2026 · Muhammet Cengiz, Oktay Bozkurt, et al. · Scientific Reports · 1
PDF
Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study
2026 · Mustafa Ersoy, Umut Kefeli, et al. · Frontiers in Immunology · 1
PDF
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma
2026 · Caner Kapar, Oğuzcan Özkan, et al. · Immunotherapy
Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
2026 · Emre Çakır, Didem Divriklioğlu, et al. · International Journal of Cancer
PDF
Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · BMC Cancer
Comparison of 24 Versus 46-Hour 5-FU Infusion Durations in the Perioperative FLOT Therapy for Gastric Cancer
2026 · Savas Gokcek, Pervin Can Sancı, et al. · Medicina
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
2026 · Neslihan Özyurt, Ali Alkan, et al. · Cancers
PDF
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)
2026 · Cihan Erol, Esra Zeynelgil, et al. · Clinical & Translational Oncology
546P HER2-low status in resectable gastric cancer: An underrecognized subgroup with distinct survival outcomes
2026 · I. Deliktas Onur, H.G. Frat, et al. · Annals of Oncology
PDF
559eP Perioperative versus adjuvant chemotherapy in gastric cancer: A retrospective cohort comparison of treatment effectiveness
2026 · I. Deliktas Onur, H.G. Frat, et al. · Annals of Oncology
PDF
Prognostic and Predictive Significance of Body Mass Index in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy: A Retrospective Multicenter Cohort Study
2026 · Pervin Can Şancı, Mustafa Seyyar, et al. · Journal of Clinical Medicine
Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study
2026 · Anıl Karakayalı, Mustafa Seyyar, et al. · Medicina
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study
2026 · Sedat Yildirim, Ozlem Nuray Sever, et al. · Clinical Medicine Insights Oncology
Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab
2026 · Erdem Kolemen, Kazım Uygun, et al. · Discover Oncology
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab
2026 · Gözde Ağdaş, Duygu Bayir, et al. · Scientific Reports
PDF
Real-World Outcomes of Irinotecan–Bevacizumab Therapy in Recurrent Brain Tumors: A Retrospective Cohort Study
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer
2026 · Muhammet Cengiz, Oktay Bozkurt, et al. · Discover Oncology
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study
2026 · Mehmet Cihan İcli, Deniz Can Guven, et al. · Journal of Clinical Medicine
PDF
Works count: 45
Citation count: 55
H-index: 4
I10-index: 1
Year
Topic
Type